Jasper Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $23.8M
- Price
- $0.7156
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.52%
- Volume
- 95.1K
About
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Quick stats
Shares outstanding33.3M
Computed float22.7M
Float / shares68.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001788028
AI Summary
AI-generated1/6
majorbullishearnings
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jasper Therapeutics announced the closing of its acquisition of Kira Pharmaceuticals, effective July 16, alongside a concurrent PIPE financing that raised $132 million in gross proceeds.
Management stated that the combined company has sufficient capital to fund planned operations through the second half of 2028, supporting the advancement of its expanded pipeline including lead assets KP-104 and briquilimab.
For the fiscal second quarter ended June 30, Jasper reported a net loss of $2.8 million, or $0.10 per share, with research and development expenses totaling $5.1 million.
Red flags
- Cash balance of $7.3M at June 30 was low prior to July financing close
- Common stockholders' equity is minimal ($1.4M)